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Objective. Nutritional deficiencies have been associatedwith cognitive decline andmooddisturbances. Vitamin intake can influence
mood and randomized controlled trials have demonstrated that multivitamin supplements are capable of reducing mild symptoms
of mood dysfunction. However, few studies have focussed on healthy older women. Methods. This study investigated the effects
of four weeks’ multivitamin supplementation on mood in 76 healthy women aged 50–75 years. Mood was assessed before and
after intervention in the laboratory using measures of current mood and retrospective experiences of mood over the past week
or longer. Mobile phones were used to assess changes in real-time mood ratings, twice weekly in the home. Results. There were
no multivitamin-related benefits identified for measures of current mood or reflections of recent mood when measured in the
laboratory. In-home assessments,wheremoodwas rated several hours after dose, revealedmultivitamin supplementation improved
ratings of stress, with a trend to reduce mental fatigue. Conclusions. Over four weeks, subtle changes to stress produced by
multivitamin supplementation in healthy older women may not be detected when only pre- and posttreatment mood is captured.
In-home mobile phone-based assessments may bemore sensitive to the effects of nutritional interventions compared to traditional
in-laboratory assessments.
1. Introduction
Vitamin insufficiency is common amongst older people [1,
2] and can lead to detriments to neurological function [3].
For instance, suboptimal intake of vitamins and minerals
including folate, vitamin B6, vitamin B12, and zinc has been
associated with mild psychiatric symptoms [4] and mood
disorders in older people [5, 6]. In addition to psychiatric
disturbances, deficiency of selected nutrients including folate
and vitamin B12 has also been implicated in dementia [7].
Depression and anxiety represent significant risk factors for
cognitive decline and dementia [8, 9]. Importantly, these
dementia risk factors are modifiable and can serve as poten-
tial targets for intervention.
Multivitamins contain a range of B vitamins, as well as
antioxidant vitamins and minerals which exert effects on the
central nervous system including synthesis of catecholamine
neurotransmitters and serotonin [10, 11]. The potential for
multivitamins to modify mood has been demonstrated in a
meta-analysis of eight randomized controlled trials (RCTs)
which indicated that multivitamin use over a period of ≥4
weeks can reduce mild symptoms of mood dysfunction in
healthy people, free from clinical mood disorders [12]. Only
one of these trials focussed exclusively on people over the age
of 50 years [13], demonstrating that, in men aged 50–70 years,
eight weeks’ supplementation with a multivitamin mineral
and herbal (MVMH) formula improved ratings of current
mood as well as reflections of mood over the preceding week.
It has been suggested that micronutrient interventions
should show larger effects on mood when measured using
near-to-real-time assessments, which permit mood to be
tracked on a momentary basis, than when assessed by
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measures which rate experiences of mood over the past week
ormonth [14].Thismay be due to effects ofmicronutrients on
neurotransmitters, as neurotransmitter and hormonal influ-
ences have more direct associations with immediate mood
responses compared to delayed reflections on mood based
on a longer time period [14, 15]. Our recent examination of
acute effects of multivitamin supplementation conducted in
women aged 50–75 years demonstrated benefits to general
mood and perceived stress one to two hours after MVMH
supplementation [16]. These findings indicate that, in older
people, mood improvements can arise in the hours following
multivitamin supplementation. Therefore a supplementation
period of several months may not be necessary to detect
mood improvements in older people due to multivitamin
supplementation. For this reason there is a need to identify
mood measures that employ a suitable time scale to best
detect mood changes in shorter term intervention trials.
Ecological momentary assessment (EMA) is a method-
ology which enables an individual to report on symptoms,
mood, and other behavioural parameters close in time to
experience, and these reports are obtained many times over
the course of a study [17]. EMA can provide real-time
measures of mood and affords greater assessment of dynamic
processes (i.e., change in mood over time) than laboratory
based assessments [18].There is emerging evidence that EMA
methodsmay be particularly sensitive to themood enhancing
effects of multivitamin supplementation. In healthy young
people, four weeks’ multivitamin supplementation resulted
in increased mental stamina, physical stamina, and con-
centration when mood was rated weekly on mobile phone
devices [19] and four months’ multivitamin supplementation
improved ratings of current stress, physical fatigue, and
anxiety using similar methodology [20]. By contrast, there
were no benefits of multivitamins to mood or general well-
being when assessments were conducted in a laboratory
setting using traditional pretreatment/posttreatment mood
measurement [20]. While these studies measured mood at
multiple time points outside of the laboratory setting, the
rates of mood changes were not examined in a continuous
manner. To date, no RCTs have utilised EMA methodology
to investigate the time course of multivitamin-related mood
changes in older people.
This investigation extends our examination of acute
effects of multivitamin supplements in older women [16]
and reports the results of a longer four-week supplemen-
tation period in the same participant sample, using the
same MVMH preparation. Our analysis from the acute time
point identified immediate mood improvements, particularly
improvements to stress, one to two hours afterMVMH intake
[16]. In the current studymoodwas assessed in the laboratory
using standard mood measures which rated retrospective
experiences of mood over the past week or longer, as well as
using assessments which rated current experiences of mood.
We set out to examine whether ratings of current mood,
including energy levels, alertness, stress, and anxiety, would
be more sensitive to the effects of four weeks’ multivitamin
mineral and herbal (MVMH) supplementation compared to
retrospective mood measures. A further aim of this study
was to assess real-time mood changes due to the MVMH
supplements over the four-week period. To achieve this
purpose, mood was rated in the home, twice weekly using
mobile phones.
2. Methods
2.1. Trial Design and Randomization. This study followed
a double-blind, placebo-controlled, parallel group, random-
ized design. Participants were allocated to receive either the
MVMH formula or a placebo matched for appearance, smell,
and taste. Participants were randomized in blocks of 4, with a
ratio of 1 : 1 using a computer generated sequence. Random-
ization was implemented by personnel not involved in the
trial, using sequentially numbered treatments. The study pro-
tocol was approved by the Swinburne University of Technol-
ogy Human Research Ethics Committee (SUHREC) and was
carried out in accordance with the Declaration of Helsinki.
All participants signed a consent form prior to enrolment in
the trial. The trial is registered as the “Behavioural Effects
of Multivitamin Supplements” study on the Australian New
Zealand Clinical Trials Registry (ACTRN12613001087741).
Data collection took place between November 2013 and July
2014.
2.2. Participants. The sample consisted of 76 community
dwelling females aged 50–75 years (M = 63.6 years, SD =
6.4 years), who were not currently engaged in full-time
employment. We focussed on this age range as previous work
by our group has identified mood benefits due to multivi-
tamin supplementation in men aged 50–70 years [13], but
relevant research in older women is lacking. Participants were
recruited from the community using an existing database and
via newspaper and post advertisements. All participants were
in good health, English speaking, nonsmokers, and free from
diabetes, cardiovascular disease, dementia, stroke, and other
neurological conditions. Further exclusion criteria included
a history of head trauma, alcohol abuse, clinically diagnosed
depression, anxiety, or other psychiatric disorders, and use
of antidepressant medication, antianxiety medication, anti-
cholinergic drugs, acetylcholinesterase inhibitors, or high-
dose anticoagulants. Participants who received a score below
25 on the Mini Mental State Examination (MMSE) [21] were
ineligible as this score may indicate the presence of cognitive
decline. All participants were required to abstain from using
vitamin E, multivitamins, vitamin B complex, ginkgo biloba,
fish oils, and St John’s Wort supplementation for 4 weeks
preceding the first study visit and for the duration of the study.
2.3. Interventions. The MVMH supplement was Swisse
Women’s 50+ Ultivite (Australian Register of Therapeutic
Goods ID: 187121). The study treatment was given orally
in tablet form. Supplements were packaged in blister packs
containing 7 supplements labelled with each day of the
week. Each participant received an opaque box containing
5 blister packs (35 supplements). Participants were required
to take one tablet daily with breakfast for 4 weeks (∼30
supplements). Table 1 lists the ingredients of theMVMH sup-
plement. As shown in Table 1 the majority of the non-MVM
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Table 1: Ingredients of Swisse Women’s 50+ Ultivite formula.
Component Daily dose
Retinyl acetate (equiv. to 2500 IU of vitamin A) 862.5 𝜇g
D-Alpha-tocopheryl acid succinate (equiv. to vitamin E 30.25 IU) 20mg
Thiamine hydrochloride (vitamin B1) 30mg
Riboflavin (vitamin B2) 30mg
Nicotinamide (vitamin B3) 20mg
Calcium pantothenate (vitamin B5) (equiv. to pantothenic acid 68.7mg) 70mg
Pyridoxine hydrochloride (vitamin B6) (equiv. to pyridoxine 20.56mg) 30mg
Cyanocobalamin (vitamin B12) 115 𝜇g
Cholecalciferol (vitamin D3) (equiv. to vitamin D 200 IU) 5𝜇g
Biotin (vitamin H) 150𝜇g
Folic acid 500𝜇g
Calcium ascorbate dihydrate (vitamin C) (equiv. to ascorbic acid 165.3mg) 200mg
Phytomenadione (vitamin K) 60𝜇g
Zinc amino acid chelate (equiv. to zinc 20mg) 75mg
Calcium orotate (equiv. to calcium 10mg) 100mg
Magnesium aspartate dihydrate (equiv. to magnesium 6.74mg) 100mg
Selenomethionine (equiv. to selenium 26mcg) 65 𝜇g
Molybdenum trioxide (equiv. to molybdenum 45𝜇g) 67.5 𝜇g
Chromium picolinate (equiv. to chromium 50𝜇g) 402𝜇g
Manganese amino acid chelate (equiv. to manganese 4mg) 40mg
Ferrous fumarate (equiv. to iron 5mg) 16.01mg
Copper gluconate (equiv. to copper 1.7mg) 8.57mg
Potassium iodide (equiv. to iodine 149.83 mcg) (equiv. to potassium 46.18mcg) 196 𝜇g
Lactobacillus rhamnosus 80 million organisms
Lactobacillus acidophilus 80 million organisms
Bifidobacterium longum 35 million organisms
Citrus bioflavonoids extract 20mg
Vaccinium macrocarpon fruit dry (patented cranberry Pacran) 800mg
Silybum marianum dry fruit (St. Mary’s thistle) (equiv. to flavanolignans calculated as silybin 17.14mg) 1500mg
Ginkgo biloba leaf dry (maidenhair tree) (equiv. to ginkgo flavonglycosides 4.8mg and ginkgolides and
bilobalide 1.2mg) 1000mg
Turnera diffusa leaf dry (damiana) 500mg
Scutellaria lateriflora herb dry (skullcap) 50mg
Vitis vinifera dry seed (grape seed) (equiv. to procyanidins 7.9mg) 1000mg
Urtica dioica leaf dry (nettle) 100mg
Ubidecarenone (Coenzyme Q10) (from patented ultrasome CoQ10) 2mg
Cynara scolymus leaf dry (globe artichoke) 50mg
Cimicifuga racemosa root & rhizome dry (black cohosh) 200mg
Curcuma longa rhizome dry (turmeric) 100mg
Withania somnifera root dry (ashwagandha) 500mg
Crataegus monogyna fruit dry (hawthorn) 100mg
Silica colloidal anhydrous (equiv. to silicon 9.35mg) 20mg
Bacopa monnieri whole plant dry (Bacopa) (equiv. to bacosides calculated as bacoside A 1.125mg) 50 mg
Lecithin powder-soy phosphatidylserine enriched soy (equiv. to phosphatidylserine 2mg) 10mg
Spearmint oil 2mg
Vaccinium myrtillus fruit dry (bilberry) (equiv. to anthocyanosides 324mcg) 100mg
Tagetes erecta flower dry (marigold) (lutein esters calculated as lutein (of Tagetes erecta) 1mg) 100mg
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ingredients are at subtherapeutic levels with the exceptions
of ashwagandha, ginkgo, and grape seed. The placebo tablets
contained starch and a small amount of riboflavin (2mg)
to give them a similar smell and colouration of the urine.
Participants were required to abstain from the treatment on
the day of posttreatment testing. Treatment compliance was
determined using a daily tablet taking log and by counting
remaining tablets at the posttreatment assessment.
2.4. Sample Size. Ameta-analysis [12] has indicated that mul-
tivitamin formulas, with comparable doses of B vitamins to
the current study, exert small to medium sized effects (stan-
dard mean difference = .29) on moodmeasures including the
GeneralHealthQuestionnaire. Power analysis was conducted
using G∗Power 3.1.3. To have 80% chance of detecting an
effect size of this magnitude (𝐹 = .15) in a two-armed study
(multivitamin, placebo) with at least 3 time points it was
determined that a total sample of 75 participants would be
required (alpha level = .05).
2.5. Procedure. Potential participants were screened over the
telephone to determine initial eligibility. Those who fulfilled
the eligibility criteria were invited to attend the first session
where additional screening and baseline and acute data
(published elsewhere, [16]) were collected.
2.5.1. Baseline Visit. Participants attended the baseline lab-
oratory based assessment between 0900 and 1100 hours.
On the day of the baseline visit participants were asked to
refrain from caffeine ingestion and to consume their “usual”
breakfast. The participant’s breakfast was recorded and they
were requested to consume the same breakfast on the day of
the posttreatment study visit. At the baseline visit, partici-
pants provided informed consent and completed a medical
health questionnaire and the MMSE prior to enrolment
in the study. Participants completed baseline retrospective
mood ratings and current mood ratings using a mobile
phone device, as well as the cognitive assessments, prior to
being randomized to receive the MVMH formula or placebo.
Participants completed a brief food frequency questionnaire
which assessed general intake of 29 different foods over the
past 12months. Daily serves of fruit and vegetable intake were
scored on a 6-point Likert scale from 0 (none) to 5 (4 or
more).
2.5.2. Mood Assessments in the Home. Participants were
provided with a mobile phone device and were instructed to
rate their current mood using Visual Analogue Scales on two
days each week for the four-week period. Participants were
asked to ensure there were at least two days separating each
mood report and that mood reports were completed after
MVMH intake for that day. Participants were requested to
complete the mood assessments at 1000 or 1500 hours and to
ensure they completed the assessments at both times across
the intervention period.
2.5.3. Posttreatment Visit. Participants returned for their post
treatment appointment 4 weeks later at the same time of day
as their baseline visit. All moodmeasures were repeated, with
exception of the 1-hour postdose assessment.
2.6. Measures
2.6.1. Ratings of Current Mood. The State-Trait Anxiety
Inventory-State (STAI-S) assesses intensity of individual’s
current state of anxiety using 20 items [22]. Scores range from
20 to 80 with higher scores indicating greater anxiety. Partic-
ipants also rated their current mood using scales presented
on mobile phone devices both during the study visits and at
home. The Bond Lader Visual Analogue Scales (VAS) [23]
were used to assess feelings of alertness, contentedness, and
calmness. Participants marked the position of their current
subjective state on a horizontal line anchored at either end
by adjective pairs (e.g., happy-sad). Each line was scored
as the percentage of the total distance from the negative
anchor, with higher scores indicating more positive mood
states. The alertness, contentedness, and calmness subscales
were calculated from 16 adjective pairs. Additional VAS
measures were used to assess current levels of stress, anxiety,
concentration, physical fatigue, and mental fatigue on lines
with end-points labelled “Not at all” and “Extremely.” Each
scale provided a single subjective score between 0 and 100,
with lower scores indicative of more desirable mood states on
themood scales and higher energy levels on the fatigue scales.
Higher scores on the concentration item were indicative of
greater ability to concentrate.
2.6.2. General Health Questionnaire. Participants completed
a number of pen-and-paper measures designed for use in
nonclinical samples. The General Health Questionnaire-28
(GHQ-28) [24] assesses general mild psychiatric symptoms
experienced over the past week using 28 items relevant
to health-related quality of life. In nonclinical samples,
improved mood ratings have been observed on the GHQ
following multivitamin supplementation of ≥28 days [12].
Scores on the GHQ-28 range from 0 to 84, with lower scores
indicating better health-related quality of life. Participants
completed the General Health Questionnaire (GHQ) at an
additional 2-week time point in the home and returned the
questionnaire via mail.
2.6.3. Additional Retrospective Mood Measures. All other
pen-and-paper measures were completed at baseline and
posttreatment study visits only. The Hospital Anxiety and
Depression Scale (HADS) [25] is a commonly used measure
designed to screen for mood disorders in general (nonpsy-
chiatric) medical outpatients. The HADS provides a brief
measure of anxiety and depression experienced over the past
week. Scores on each subscale range from 0 to 21, with
higher scores indicating more severe anxiety or depression.
The Perceived Stress Scale (PSS) [26] was used to measure
the degree to which respondents viewed situations which
occurred over the past month as stressful. Scores on the PSS
range from 0 to 40 with higher scores indicating higher levels
of perceived stress.TheChalder Fatigue Scale [27]was used to
measure severity of symptoms relating to physical andmental
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Randomized 
Invited to participate (n = 230)
Screened for eligibility (n = 142)
Excluded (n = 66)
(i) Not meeting inclusion criteria (n = 36)
(ii) Declined to participate (n = 30)
Allocation
Allocated to multivitamin group (n = 39)
Follow up
Withdrawn (n = 2)
Major surgery (n = 1)
Query side effect (n = 1)
Analysis
Analysed (n = 37)
Allocation
Allocated to placebo group (n = 37)
Follow up
Withdrawn (n = 1)
Personal reasons (n = 1)
Analysis
Analysed (n = 36)
Figure 1: Recruitment and retention flowchart.
fatigue experienced over the past week. The scale consists
of 14 items. Scores range from 0 to 42, with higher scores
indicating greater fatigue.
2.7. Analysis. Statistical analyses were carried out in SPSS
version 22. Independent groups 𝑡-tests were used to examine
baseline group difference in age, body mass index, and
education. Multivariate analysis of variance (MANOVA) was
used to examine baseline group differences in mood.
Education was controlled for when examining all mood
outcomes; 2 (treatment: multivitamin, placebo) × 2 (time:
baseline, posttreatment) repeated mixed methods MAN-
COVA was conducted for the VAS and STAI measures of
current mood.
A 2 (treatment: multivitamin, placebo) × 3 (time: base-
line, 2 weeks, and posttreatment) MANCOVA was used for
the analysis of the subscales of the GHQ-28. To avoid mul-
ticollinearity the total GHQ score was analysed in a separate
ANCOVA model. An additional 2 (treatment: multivitamin,
placebo) × 2 (time: baseline, posttreatment) MANCOVAwas
conducted for the Chalder Fatigue Scale, HADS, and PSS.
Secondary analysis was conducted on data from the EMA
mobile phone VAS assessments using logistic longitudinal
multilevel modelling in HLM7. This analysis was conducted
to examine the dynamic effects of the MVMH formula on
mood over time.TheVAS scoreswere highly clustered around
two distinct values, indicating they were not suitable for
transformation. As these values represented the default low
and high scores in the mobile phone program, VAS scores
were recoded in binary form as below the midpoint ≤50 or
above the midpoint >50.The default scores refer to the scores
obtained on the scale if the participant pressed the left button
first (score of 24 out of 100) or right button first (score of 76
out of 100).
Approximately eight time points were included in the
multilevel analysis for each participant, commencing at the
baseline laboratory session and concluding at the final in-
home assessment.
3. Results
Participants were 39 women allocated to the multivitamin
group and 37 allocated to placebo group. The participant
recruitment flowchart is shown inFigure 1.Three participants
withdrew during the course of the study leaving a total of 37
individuals in the multivitamin group and 36 in the placebo
group (4% withdrawal rate).
Demographic details of the participant sample are shown
in Table 2. Details of medication use have been reported
elsewhere [16]. Independent 𝑡-tests indicated there were no
significant group differences in participant age or body mass
index (kg/m2); however participants assigned the MVMH
treatment had completed significantly more years of educa-
tion (𝑡(74) = 2.19,𝑝 < .05).Themajority of participants were
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Table 2: Participant demographics at baseline.
Characteristic MultivitaminM (SD)
Placebo
M (SD)
Age 64.4 (6.3) 62.8 (6.4)
Body mass index 24.4 (3.5) 26.3 (5.0)
Years of education 17 (3.4) 15.4 (3.3)∗
Employed part time (% of yes) 36% 41%
Retired (% yes) 44% 49%
∗𝑝 < .05.
either retired (46%) or working part time/casual hours (38%).
The majority of participants reported consuming 2 serves of
fruit per day (56% multivitamin group, 57% placebo group)
and 3 serves of vegetables (49% multivitamin group, 33%
placebo group). Chi square tests of independence indicated
there were no interactions between treatment group and daily
portions of fruit (𝜒2(4) = 2.91, 𝑝 = .57) or vegetable intake
fruit (𝜒2(4) = 4.22, 𝑝 = .38). Average compliance for both
groups was 99% (SD = 3), with no participants dropping
below 89% adherence. On average participants completed 7
(SD = 1.2) mood assessments in the home using the mobile
phone device. MANOVA analysis indicated at baseline there
were no significant group differences between mood ratings
on the GHQ measures (𝐹(4, 71) = .66, Wilk’s 𝜆 = .96, and
𝑝 = .62), visual analogue measures, and STAI (𝐹(9, 66) = .85,
Wilk’s 𝜆 = .90, and 𝑝 = .58) or other retrospective mood
measures (𝐹(5, 70) = 1.73,Wilk’s 𝜆 = .89, and 𝑝 = .14).
3.1. Laboratory Mood Assessments. Baseline and posttreat-
ment mood scores are shown in Table 3. In terms of the effect
of the MVMH formula on mood, there was no significant
time × treatment interaction for the GHQ-28 total score
(𝐹(2, 128) = .78, 𝑝 = .46). A significant time × treat-
ment interaction was identified for the GHQ-28 subscores
(𝐹(8, 57) = 2.27, Wilk’s 𝜆 = .76, and 𝑝 = .04). However, the
univariate time× treatment interactionwas not significant for
any of these measures in isolation. There were no significant
time × treatment interactions for the Bond Lader VAS,
additional VAS, and STAI ratings of currentmood (𝐹(9, 60) =
.97, Wilk’s 𝜆 = .87, and 𝑝 = .50). Similarly there were
no significant time × treatment interactions for the other
retrospective mood scales including the Chalder Fatigue total
score and subscales, the HADS, and the PSS (𝐹(5, 65) = .94,
Wilk’s 𝜆 = .93, and 𝑝 = .47).
3.2. EMA Assessments of Current Mood in the Home. In
total 54% of mood ratings were completed in the morning,
with 40% completed in the the afternoon and 6% in the
evening. This was highly comparable for both treatment
groups. Slope and odds ratio values for each group are
shown in Table 4 while controlling for years of education.
A significant interaction between time and treatment was
identified for stress (𝑡(71) = 2.82, 𝑝 = .006) and so was a very
nearly significant interaction effect formental fatigue (𝑡(71) =
1.957, 𝑝 = .054). Odds ratios indicate the daily reduction
in stress was on average 5.3% greater in the multivitamin
Treatment
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Figure 2: Change in the probability of stress ratings >50, assessed
biweekly using mobile phone devices, commencing at baseline and
concluding at the final in-home assessment for someone with 12
years of education.
group than the placebo and reduction in mental fatigue was
on average 3.7% greater in the multivitamin group than in the
placebo group. Changes in stress and mental fatigue ratings,
concluding at the final in-home assessment, are shown in
Figures 2 and 3, respectively.
4. Discussion
This study of healthy older women found no benefit of four
weeks’ MVMH supplementation to ratings of retrospective
or current experiences of mood. However, improvements to
stress and a trend for mental fatigue to be reduced were
observed when mood was rated in the home on multiple
occasions, using mobile phone devices. These results differ
from trials which have demonstrated that a period of 4
weeks’ multivitamin supplementation is sufficient to induce
mood benefits to similar retrospective measures in healthy
younger adults [28, 29]. However findings of mood benefits
detected outside the laboratory are consistent with results
of other researchers who have utilised comparable mobile
phone based assessments [19, 20].
The present study did not identify multivitamin-related
benefits to measures of current mood or retrospective mood,
when rated in the laboratory. Improvements to both cat-
egories of mood ratings on several of the same measures
included in the present study, including the GHQ and VAS
mood scales, have previously been found to benefit from
multivitamin supplementation inmen aged 50–69 years, over
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Table 3: Means and standard deviations for the mood assessments at baseline and 4 weeks after treatment.
Measure Group Baseline Midpoint Posttreatment
𝑁 M SD M SD M SD
General Health Questionnaire
Total Multivitamin 35 15.06 6.65 14.31 5.86 14.47 5.48
Placebo 33 15.24 6.74 13.00 6.01 12.79 5.84
Somatic Multivitamin 35 3.60 2.76 4.03 3.22 4.29 3.04
Placebo 33 4.33 3.01 3.64 3.20 3.21 2.38
Anxiety Multivitamin 35 3.57 2.76 3.42 2.52 3.20 2.58
Placebo 33 3.48 2.58 2.97 2.56 3.00 2.52
Social dysfunction Multivitamin 35 6.83 1.67 6.23 1.68 6.51 1.40
Placebo 33 6.82 1.89 5.89 1.58 6.12 1.52
Depression Multivitamin 35 1.06 2.09 0.63 1.33 0.46 1.12
Placebo 33 0.61 1.52 0.52 1.56 0.45 1.50
Chalder Fatigue Scale
Total Multivitamin 37 16.00 4.33 13.35 3.22
Placebo 36 14.47 3.75 13.03 3.20
Physical Multivitamin 37 8.83 2.63 7.47 1.66
Placebo 36 8.11 2.61 7.31 2.19
Mental Multivitamin 37 7.05 2.17 5.62 1.40
Placebo 36 6.36 1.53 5.72 1.39
Hospital Anxiety and Depression Scale
Anxiety Multivitamin 37 4.46 2.30 3.81 2.08
Placebo 36 4.33 2.69 4.03 3.15
Depression Multivitamin 37 2.16 2.10 1.35 1.57
Placebo 36 2.23 1.75 1.42 2.00
Perceived Stress Scale
Multivitamin 37 19.05 3.21 18.70 1.90
Placebo 35 18.40 2.08 17.74 2.00
State-Trait Anxiety Inventory
State version Multivitamin 37 32.81 10.27 28.32 6.85
Placebo 35 30.54 9.09 27.06 9.05
Visual Analogue Scales
Alertness Multivitamin 37 68.52 17.51 72.89 16.52
Placebo 35 70.83 16.19 75.62 17.96
Contentedness Multivitamin 37 77.57 16.88 81.55 13.89
Placebo 35 81.47 16.32 83.45 16.58
Calmness Multivitamin 37 66.43 21.74 74.09 16.66
Placebo 35 74.26 18.92 77.20 19.52
Stress Multivitamin 37 21.76 21.61 12.38 13.63
Placebo 35 14.77 17.81 14.09 17.15
Concentration Multivitamin 37 65.95 28.81 72.62 20.40
Placebo 35 61.83 26.65 66.89 29.76
Anxiety Multivitamin 37 16.24 19.15 12.97 15.86
Placebo 35 14.60 19.24 10.69 14.27
Mental fatigue Multivitamin 37 23.24 24.14 18.22 20.91
Placebo 35 23.77 21.98 19.17 19.24
Physical fatigue Multivitamin 37 21.19 23.19 20.05 23.03
Placebo 35 17.74 18.89 19.09 20.74
𝑁 = represents participants included in the pretreatment to posttreatment analysis.
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Table 4: Fixed effects coefficients and daily odds ratios for mobile phone ratings of mood over the intervention period controlling for years
of education.
Mood rating Treatment Daily odds ratio Odds ratio test Test difference odds ratios
Estimate 95% CI 𝑡(71) 𝑝 value 𝑡(71) 𝑝 value
Alertness Multivitamin 1.052 (1.021, 1.084) 3.391 .001 1.300 .198
Placebo 1.023 (.992, 1.055) 1.484 .142
Contentedness Multivitamin 1.008 (.988, 1.029) .832 .408 .483 .631
Placebo 1.017 (.990, 1.044) 1.241 .219
Calmness Multivitamin 1.044 (1.020, 1.067) 3.781 <.001 −.550 .584
Placebo 1.035 (1.014, 1.056) 3.416 .001
Stress Multivitamin .941 (.918, .965) −4.802 <.001 2.820 .006
Placebo .994 (.965, 1.023) −.442 .660
Concentration Multivitamin 1.022 (.995, 1.051) 1.605 .113 .220 .827
Placebo 1.026 (1.002, 1.052) 2.133 .036
Anxiety Multivitamin .957 (.930, .984) −3.147 .002 .855 .395
Placebo .973 (.947, .999) −1.630 .107
Mental fatigue Multivitamin .928 (.900, .956) −4.941 <.001 1.957 .054
Placebo .965 (.940, .99) −2.802 .007
Physical fatigue Multivitamin .963 (.935, .992) −2.514 .014 1.682 .097
Placebo 1.000 (.968, 1.033) −.015 .988
0.00
0.10
0.20
0.30
0.40
Ex
pe
ct
ed
 p
ro
ba
bi
lit
y 
of
 m
en
ta
l f
at
ig
ue
 sc
or
es
>
5
0
7 14 21 280
(Days)
Treatment
Placebo
Multivitamin
Figure 3: Change in the probability of mental fatigue ratings
>50 assessed biweekly using mobile phone devices, commencing
at baseline and concluding at the final in-home assessment for
someone with 12 years of education.
a period of eight weeks, using a similar MVMH formulation
[13]. These results suggest the mood measures used in the
present study were suitable to detect mood changes due to the
MVMH formula. Furthermore, our analysis from an acute
time point in the same study identified immediate mood
improvements, particularly improvements to stress, one to
two hours after MVMH intake [16]. These findings indicate
that the cohort under investigation was responsive to the
MVMH treatment and this observation was confirmed in the
EMAanalysis ofmobile phone data undertaken in the current
investigation. When considered together the results of this
study suggest that the four-week intervention duration may
not have been sufficient to induce ongoing mood changes
which could be detected in the laboratory when participants
had been instructed to abstain from taking the MVMH
formula.
There were no multivitamin-related improvements to
current mood when measured in the laboratory; however a
gradual reduction in stress and mental fatigue was observed
in the home across repeated measurements. These results
do need to be interpreted with a certain degree of caution
as the data was required to be converted into binary form,
due to clustering of scores. There are several factors which
may have influenced differential home and laboratory results.
Firstly, for this cohort the home environment is likely to
be less stressful and thus less likely to mask any beneficial
mood effects compared to the laboratory. An important
consideration is that participants were required to abstain
from taking the treatment on the day of the laboratory
based follow-up assessments; however at-home biweekly
assessments were completed after MVMH intake. Our prior
analysis of acute effects of MVMH supplementation from
this trial indicated that mood improvements, particularly
improvements to stress, occurred 1-2 hours after dose, in the
same participant sample, using the sameMVMHpreparation
[16]. Similar immediate mood benefits of multivitamin sup-
plements have been reported by others in younger cohorts
[30, 31].
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When considered along with previous observations of
an acute mood benefit arising from multivitamin supple-
mentation [16], results from the current study suggest that
the mood enhancements captured by the EMA method-
ology may partially reflect more immediate effects of the
MVMH formula induced by taking the supplement earlier
on the same day as the mood ratings were completed.
This interpretation would be consistent with the results of
Pipingas et al. [20] who identified benefits to current ratings
of mood only on days when participants had consumed
the MVMH supplement. Our study extends the findings
of Pipingas et al. [20] by demonstrating that multivitamin
supplementation can lead to an ongoing reduction in stress
and mental fatigue over time and not just when discrete
trial end-points are considered. These findings indicate that
multivitamin-related benefits to moodmay reflect short term
postintake mood improvements coupled with a cumulative
effectwhich increases over time.While future studieswanting
to solely focus on chronic effects of multivitamins should
consider abstinence from treatment prior to posttreatment
assessments, the time course and limits of both the acute
and cumulative effects of multivitamin supplementation also
merit further investigation.
There is evidence from a meta-analysis conducted by
Long and Benton [12], which indicates that, across studies,
multivitamins significantly improved both stress and mental
fatigue facets of mood. This observation has been reported
across time frames ranging from hours [16], weeks [28, 29],
and through to months after dose [32]. In terms of a putative
mechanism, vitamins B2 and B6 and niacin are necessary
for amino acid metabolism required for the production of
serotonin, a neurotransmitter important for mood regulation
[10]. Additionally, vitamins B12 and folate and B6 are crucial
for one-carbon metabolism, a process through which S-
adenosylmethionine (SAMe) is formed. SAMe, the major
methyl donor in the body is critical for the production
of the neurotransmitters norepinephrine and dopamine,
as well as serotonin [33]. Others have shown that three
months’ supplementation with a drink containing multivita-
mins and minerals increased levels of serum serotonin, with
tryptophan levels increasing over six months [34]. Serum
tryptophan levels have been demonstrated to be a useful
biomarker to distinguish moderate and severe depression
from healthy controls [35], indicating a relationship with
mood regulation. Whether changes to levels of serotonin or
tryptophan occurred in the present study, especially given
the shorter time period, cannot be confirmed. Stress and
mental fatigue signify negative aspects of affect, with the
former representing a high energy state of activation and the
latter a low energy state of deactivation [36]. Greater negative
reactivity to stressors has been linked with risk of depression
and anxiety in older people [37, 38]; therefore interventions
which can reduce the affective impact of psychological stress
may contribute to a reduced vulnerability to depression
and anxiety. Furthermore, susceptibility to stress has been
associated with a greater risk of Alzheimer’s disease [39];
therefore reducing stress levels may have implications for
cognitive health. Stress and mental fatigue benefits were
observed for measures of current mood when measured in
the home, rather than retrospective mood ratings, supporting
the idea that real-time measures of mood may be more
sensitive to the positive effects of nutritional interventions
compared to traditional measures [14].
There are several limitations of the study which should
be addressed. Mood was rated retrospectively in the lab-
oratory (≥1 week of recall time frame) at the four-week
posttreatment visit, when participants were instructed to
refrain from taking the MVMH. Future studies need to
fully ascertain whether abstaining from MVMH treatment
on the day of follow-up assessments attenuates any mood
benefits. Differences between mood states when rated in
the home setting versus the laboratory also require further
investigation. Mood was not rated before dose in the home,
as participants were only instructed to rate their mood after
consuming the multivitamin. Therefore it is not possible to
determine within-day mood changes in the home setting.
We utilised the in-lab assessment as our baseline, and it is
possible that, due to the setting being the laboratory, mood
scores may have been elevated at baseline, relative to whether
assessments had taken place in a more naturalistic setting. In
contrast to previous RCTs which have examined the mood
effects of multivitamin supplements [32, 40], we did not
examine any biochemical blood measures of vitamin status.
It would have been informative to determine whether levels
of B vitamins were sufficient at baseline and whether the
MVMH formula was capable of increasing B vitamin levels
over the four-week period, given the documented association
between folate, vitamin B6, vitamin B12, andmild psychiatric
symptoms [4, 12]. The supplement used in the current
study also contained a range of 20 botanical extracts. The
majority of herbal extracts were at a subtherapeutic dosage;
however the MVMH formula contained larger extracts of
the herbs Ashwagandha and Ginkgo Biloba which have been
implicated in the regulation of mood [41] and flavonoid
containing grape seed extract which may exert effects on the
central nervous system [42].The assessment of blood vitamin
and flavonoid status at multiple time points corresponding
to mood assessments may be useful to provide mechanistic
insight into which components of the multivitamin may be
responsible for mood alterations.
Findings from this study indicate that mobile phone
devices can be used by older women to report onmood in the
context of clinical trials designed to evaluate nutritional inter-
ventions. On average participants completed 7 of the 8 mood
assessments indicating a satisfactory level of compliance in
the home setting. In this study only a basic interface was
used on the mobile phones allowing for completion of VAS
ratings but not more detailed traditional mood measures.
The use of a basic interface also led to clustering of scores
around similar values, which would not have occurred with
a touch screen application, nor on the original paper-and-
pencil versions of these measures. Nevertheless due to the
number of time points we were still able to identify greater
stress reductions for the MVMH group, compared to placebo
group, which is consistent with our findings from the acute
assessment [16]. The observation of a specific multivitamin-
related reduction in stress both acutely [16] and over the
longer 4-week period suggests that this reduction in stress
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is a valid finding. Similar results of mood improvements
detected using EMA measures but not standard pencil and
paper measures have been observed following a mindfulness
based intervention in emotionally distressed older adults
[43]. These results are important as they suggest that EMA
approaches could improve the detection of change in patient-
reported outcomes in intervention studies when compared
to standard paper-and-pencil administration [43]. It is rec-
ommended that future studies make use of smart phone
applications in order to capture a broader range of mood
assessments across a variety of situations (for a review of
alternate technology suitable for this purpose see [14]).
In summary, the results of this investigation suggest that,
over a period of four weeks, subtle changes to mood, espe-
cially stress, may not be detected when only pre- and post-
treatment mood are captured. Future research is required to
ascertain whether mood improvements due to multivitamin
supplementation are driven by an acute effect of consuming
the multivitamin [16] and therefore whether mood benefits
may be diminished when the treatment is withheld.
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